Global Information
회사소개 | 문의 | 위시리스트

Bionomics Limited : 제품 파이프라인 리뷰

Bionomics Ltd - Product Pipeline Review - 2016

리서치사 Global Markets Direct
발행일 2016년 12월 상품 코드 256101
페이지 정보 영문 47 Pages
가격
US $ 1,500 ₩ 1,776,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,552,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,500 ₩ 5,329,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


Bionomics Limited : 제품 파이프라인 리뷰 Bionomics Ltd - Product Pipeline Review - 2016
발행일 : 2016년 12월 페이지 정보 : 영문 47 Pages

Bionomics Limited는 암과 불안신경증·우울증·알츠하이머병 등 중추신경계 질환의 치료제를 개발하고 있는 바이오 제약회사입니다. 또한 면역 질환 치료제도 제공하고 있습니다.

Bionomics Limited의 치료제 개발 파이프라인 현황과 각 개발 단계 비교 분석, 약제 표적, 작용기서, 투여 경로, 분자 종류별 치료제 평가, 최신 기업 뉴스와 발표, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 전해드립니다.

Bionomics Limited의 기본 정보

Bionomics Limited의 개요

  • 주요 정보
  • 기업 정보

Bionomics Limited : R&D 개요

  • 주요 치료 범위

Bionomics Limited : 파이프라인 리뷰

  • 개발 단계별 파이프라인 제품
  • 단독요법
  • 아웃 라이선스 제품
    • 아웃 라이선스 제품/병용요법 모달리티

Bionomics Limited : 파이프라인 제품 개요

  • 임상 단계 파이프라인 제품
    • 제II상 제품/병용요법 모달리티
    • 제I상 제품/병용요법 모달리티
  • 초기 단계 파이프라인 제품
    • 전임상 제품/병용요법 모달리티
    • 디스커버리 제품/병용요법 모달리티

Bionomics Limited : 치료제 개요

  • BNC-105
  • BNC-105P
  • BNC-210
  • BL-011256
  • BNC-101
  • BNC-164
  • BNC-420
  • BNC-102
  • Programs for Cancer
  • Small Molecules to Agonize GABA-A Receptor For Epilepsy
  • Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain

Bionomics Limited : 파이프라인 분석

  • 표적별
  • 투여 경로별
  • 분자 종류별
  • 작용기서별

Bionomics Limited : 최근의 파이프라인 동향

Bionomics Limited : 휴지중인 프로젝트

Bionomics Limited : 개발이 중지된 파이프라인 제품

  • 개발이 중지된 파이프라인 제품 개요
    • Drug to Inhibit RET Kinase for Lung and Thyroid Cancer

Bionomics Limited : 본사 및 자회사 소재지

부록

도표

KSM 15.02.02

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Summary:

Global Markets Direct's, 'Bionomics Ltd - Product Pipeline Review - 2016', provides an overview of the Bionomics Ltd's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Bionomics Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the pipeline therapeutic landscape of Bionomics Ltd
  • The report provides overview of Bionomics Ltd including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Bionomics Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Bionomics Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy:

  • Evaluate Bionomics Ltd's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Bionomics Ltd
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bionomics Ltd's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bionomics Ltd Snapshot
    • Bionomics Ltd Overview
    • Key Facts
  • Bionomics Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Bionomics Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Bionomics Ltd - Pipeline Products Glance
    • Bionomics Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Bionomics Ltd - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
  • Bionomics Ltd - Drug Profiles
    • BL-011256 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNC-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNC-105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNC-164 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNC-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNC-420 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for Dyskinesia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Solid Tumors - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit MELK for Solid Tumors - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize GABA-A Receptor For Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bionomics Ltd - Pipeline Analysis
    • Bionomics Ltd - Pipeline Products by Target
    • Bionomics Ltd - Pipeline Products by Route of Administration
    • Bionomics Ltd - Pipeline Products by Molecule Type
    • Bionomics Ltd - Pipeline Products by Mechanism of Action
  • Bionomics Ltd - Dormant Projects
  • Bionomics Ltd - Discontinued Pipeline Products
  • Discontinued Pipeline Product Profiles
  • Drug to Inhibit RET Kinase for Lung and Thyroid Cancer
  • Bionomics Ltd - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Bionomics Ltd, Key Facts
  • Bionomics Ltd - Pipeline by Indication, 2016
  • Bionomics Ltd - Pipeline by Stage of Development, 2016
  • Bionomics Ltd - Monotherapy Products in Pipeline, 2016
  • Bionomics Ltd - Out-Licensed Products in Pipeline, 2016
  • Bionomics Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Bionomics Ltd - Phase II, 2016
  • Bionomics Ltd - Phase I, 2016
  • Bionomics Ltd - IND/CTA Filed, 2016
  • Bionomics Ltd - Preclinical, 2016
  • Bionomics Ltd - Pipeline by Target, 2016
  • Bionomics Ltd - Pipeline by Route of Administration, 2016
  • Bionomics Ltd - Pipeline by Molecule Type, 2016
  • Bionomics Ltd - Pipeline Products by Mechanism of Action, 2016
  • Bionomics Ltd - Dormant Developmental Projects,2016
  • Bionomics Ltd - Discontinued Pipeline Products, 2016
  • Bionomics Ltd, Subsidiaries

List of Figures

  • Bionomics Ltd - Pipeline by Top 10 Indication, 2016
  • Bionomics Ltd - Pipeline by Stage of Development, 2016
  • Bionomics Ltd - Monotherapy Products in Pipeline, 2016
  • Bionomics Ltd - Pipeline by Target, 2016
  • Bionomics Ltd - Pipeline by Route of Administration, 2016
  • Bionomics Ltd - Pipeline by Molecule Type, 2016
  • Bionomics Ltd - Pipeline Products by Mechanism of Action, 2016
Back to Top
전화 문의
F A Q